AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21729174 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.1 mL injected intradermally)
Number of subjects: 40
Study 21729174 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.1 mL injected subdermally)
Number of subjects: 40
Study 21729174 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.1 mL injected subcutaneously)
Number of subjects: 40
Study 21729174 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology on day 7 from 22 reactions in 15 patients
Number of subjects: 40
Study 21729174 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick test vs. histamine reference
Number of subjects: 40
Study 21729174 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of circulating insulin detemir‐specific antibodies by RIA before and after 3 months
Number of subjects: 40
Study 21729174 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline injection)
Number of subjects: 40
Study 19555936 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (60 mL) followed by 2 L of PEG-ELS (Prep 3)
Number of subjects: 120
Study 19555936 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (15 g) followed by 2 L of PEG-ELS (Prep 2)
Number of subjects: 120
Study 19555936 — intervention group
Group type: COMPARATOR
Intervention: Conventional volume (4 L) of PEG-ELS (Prep 1)
Number of subjects: 120
Study 17145603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide
Number of subjects: 8
Study 17145603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chlorambucil
Number of subjects: 8
Study 17145603 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and autologous or allogeneic stem cell transplantation
Number of subjects: 8
Study 17145603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine-containing regimens
Number of subjects: 8
Study 17145603 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedules including non-cross-reactive agents, such as alemtuzumab
Number of subjects: 8
Study 12932242 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% coal tar preparation
Number of subjects: 40
Study 12932242 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol cream
Number of subjects: 40
Study 10804813 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized skeletal muscle training (unilateral calf plantar flexion exercise)
Number of subjects: 7
Study 8653439 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breast milk (EBM) with added fortifier
Number of subjects: 22
Study 8653439 — intervention group
Group type: COMPARATOR
Intervention: Expressed breast milk (EBM) alone
Number of subjects: 22
Study 2071723 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 41
Study 2071723 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline therapy (25, 50, or 75 mg/day)
Number of subjects: 41
Study 6318346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐Profenid tablets (300 mg in 2 daily oral doses)
Number of subjects: 43
Study 6318346 — intervention group
Group type: COMPARATOR
Intervention: Profenid capsules (300 mg in 3 daily oral doses)
Number of subjects: 43
Study 6318346 — intervention group
Group type: COMPARATOR
Intervention: Profenid capsules
Number of subjects: 43
Study 6318346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐Profenid tablets
Number of subjects: 43
Study 30904207 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds (AS: 56 g/day)
Number of subjects: 76
Study 30904207 — intervention group
Group type: COMPARATOR
Intervention: Biscuit snack (BS)
Number of subjects: 76
Study 29572814 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS model (an innovative, comprehensive extension of the TRAnsition Coaching for Stroke program)
Number of subjects: 6000
Study 29572814 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up at 2, 30, and 60 days after discharge; clinic visit within 14 days by a nurse and advanced practice provider
Number of subjects: 6000
Study 27759780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Cephazolin (2 g) during anesthetic induction
Number of subjects: 100
Study 27759780 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 100
Study 24815851 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg/kg of palifermin
Number of subjects: 99
Study 24815851 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg/kg of palifermin
Number of subjects: 99
Study 24815851 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg/kg of palifermin
Number of subjects: 99
Study 24815851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 22905609 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone (group A, n=35)
Number of subjects: 102
Study 22905609 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone (group B, n=33)
Number of subjects: 102
Study 22905609 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP composite bone (group C, n=34)
Number of subjects: 102
Study 19464394 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study 19464394 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly conducted meta-analyses
Number of subjects: 0
Study 17552379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) intervention plus treatment as usual (mask fitting and information)
Number of subjects: 100
Study 17552379 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 100
Study 17552379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) intervention
Number of subjects: 100
Study 16336061 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (clinicians received clinical feedback reports at intake and at 6 weeks)
Number of subjects: 1374
Study 16336061 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinicians received no report)
Number of subjects: 1374
Study 11994377 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 25
Study 11994377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10193216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia using propofol
Number of subjects: 68
Study 10193216 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia using isoflurane
Number of subjects: 68
Study 8090163 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 392
Study 8090163 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 392
Study 3294189 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil (150 mg/day)
Number of subjects: 30
Study 3294189 — intervention group
Group type: COMPARATOR
Intervention: nifedipine (30 mg/day)
Number of subjects: 30
Study 31785444 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength, Hope, and Resources Program for People with PD (SHARP‐PWP)
Number of subjects: 31
Study 31785444 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (waitlist control)
Number of subjects: 31
Study 31785444 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 31
Study 31108093 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ablation regimen (1 × 10 J/cm2-clean-1 × 10 J/cm2)
Number of subjects: 104
Study 31108093 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple-single ablation regimen (1 × 10 J/cm2-no clean)
Number of subjects: 104
Study 31108093 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Standard and Simple-single)
Number of subjects: 104
Study 28755285 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily)
Number of subjects: 379
Study 28755285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 26163252 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic olfactory cleft polyp removal (group A)
Number of subjects: 17
Study 26163252 — intervention group
Group type: COMPARATOR
Intervention: Observation (cleft polyps left in place, group B)
Number of subjects: 17
Study 26163252 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 17
Study 24028801 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz)
Number of subjects: 18
Study 24028801 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 22428493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils retromolar fiberscope
Number of subjects: 40
Study 22428493 — intervention group
Group type: COMPARATOR
Intervention: Direct vision laryngoscopy (Macintosh blade)
Number of subjects: 40
Study 19538915 — intervention group
Group type: EXPERIMENTAL
Intervention: Female-specific motivational-enhancement group intervention
Number of subjects: 285
Study 19538915 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 285
Study 18693835 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based program (PG)
Number of subjects: 91
Study 18693835 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading group (RG)
Number of subjects: 91
Study 18693835 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 91
Study 15554736 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% phenylephrine in petrolatum
Number of subjects: 14
Study 15554736 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% pseudoephedrine in petrolatum
Number of subjects: 14
Study 15554736 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ephedrine in petrolatum
Number of subjects: 14
Study 15554736 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ephedrine in petrolatum
Number of subjects: 14
Study 15554736 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% phenylpropanolamine in petrolatum
Number of subjects: 14
Study 15554736 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% fepradinol in petrolatum
Number of subjects: 14
Study 15554736 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% methoxamine in petrolatum
Number of subjects: 14
Study 15554736 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% oxymetazoline in petrolatum
Number of subjects: 14
Study 15554736 — intervention group
Group type: COMPARATOR
Intervention: DMSO (negative control)
Number of subjects: 14
Study 11331560 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 667
Study 11331560 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of illness
Number of subjects: 667
Study 11331560 — intervention group
Group type: EXPERIMENTAL
Intervention: Less time living independently
Number of subjects: 667
Study 11331560 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time in hospital for psychiatric reasons
Number of subjects: 667
Study 9399198 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement (experimental)
Number of subjects: 60
Study 9399198 — intervention group
Group type: COMPARATOR
Intervention: Zinc phosphate cement (control)
Number of subjects: 60
Study 9399198 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (experimental)
Number of subjects: 60
Study 9399198 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement (control)
Number of subjects: 60
Study 9399198 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin cement (experimental)
Number of subjects: 60
Study 9399198 — intervention group
Group type: COMPARATOR
Intervention: Resin cement (control)
Number of subjects: 60
Study 8201643 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ofloxacin
Number of subjects: 33
Study 8201643 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg norfloxacin
Number of subjects: 33
Study 8201643 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg ciprofloxacin
Number of subjects: 33
Study 8201643 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcoital quinolone prophylaxis
Number of subjects: 33
Study 2953380 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizoate with mepivacaine
Number of subjects: 17
Study 2953380 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizoate with saline
Number of subjects: 17
Study 2953380 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (320 mg I/ml, osmolality 0.58 ml/kg)
Number of subjects: 17
Study 2381134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2381134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride (200 mmol/day)
Number of subjects: 15
Study 2381134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (200 mmol Na/day)
Number of subjects: 15
Study 5440568 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mug aerosol inhalation)
Number of subjects: 11
Study 5440568 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (1,000 mug aerosol inhalation)
Number of subjects: 11
Study 30845818 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus samidorphan (5 mg)
Number of subjects: 309
Study 30845818 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus samidorphan (10 mg)
Number of subjects: 309
Study 30845818 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus samidorphan (20 mg)
Number of subjects: 309
Study 30845818 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 309
Study 28803820 — intervention group
Group type: EXPERIMENTAL
Intervention: INSIGHT (1 unit/day increase in insulin dosage)
Number of subjects: 212
Study 28803820 — intervention group
Group type: COMPARATOR
Intervention: EDITION (dose adjusted by investigator at least once weekly)
Number of subjects: 212
Study 25867912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg once daily (OD)
Number of subjects: 306
Study 25867912 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin 550 mg twice daily (BD)
Number of subjects: 306
Study 23982421 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI total score (0-10) for findings at L4/L5 plus L5/S1 including Modic type I and/or II changes, posterior high intensity zone (HIZ), dark/black nucleus pulposus signal, and ≥40% disc height decrease.
Number of subjects: 170
Study 23982421 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HIZ at L5/S1.
Number of subjects: 170
Study 21420594 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 82
Study 21420594 — intervention group
Group type: COMPARATOR
Intervention: Sham-procedure control group
Number of subjects: 82
Study 21420594 — intervention group
Group type: COMPARATOR
Intervention: Fellow-eye control group
Number of subjects: 82
Study 19709782 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (experimental group)
Number of subjects: 40
Study 19709782 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 17304780 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclizine
Number of subjects: 77
Study 17304780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 15503832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hodgkin's lymphoma survivors
Number of subjects: 121
Study 15503832 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 11240116 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial processing in autistic subjects
Number of subjects: 0
Study 11240116 — intervention group
Group type: COMPARATOR
Intervention: Cerebellar influence on spatial attention
Number of subjects: 0
Study 9743848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 9743848 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study 9743848 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/Propofol
Number of subjects: 60
Study 9743848 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation induction (Sevoflurane)
Number of subjects: 60
Study 9743848 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index of 60
Number of subjects: 60
Study 8173521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-fortified enteral feeding (Jevity) for 7 weeks
Number of subjects: 11
Study 8173521 — intervention group
Group type: COMPARATOR
Intervention: Usual enteral feeding
Number of subjects: 11
Study 3265624 — intervention group
Group type: EXPERIMENTAL
Intervention: New trimethoprim/sulfamethoxazole preparation (Kepinol forte, 160 mg of trimethoprim/800 mg of sulfamethoxazole)
Number of subjects: 12
Study 3265624 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (customary in trade and registered according to the AMG 1976)
Number of subjects: 12
Study 3265624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 12
Study 29295028 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental vignettes depicting serious types of IPV with male perpetrator and female victim
Number of subjects: 599
Study 29295028 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental vignettes depicting serious types of IPV with female perpetrator and male victim
Number of subjects: 599
Study 29295028 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior IPV experiences among female respondents
Number of subjects: 599
Study 29295028 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender dynamics manipulations within IPV scenarios
Number of subjects: 599
Study 29295028 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior psychological IPV experiences
Number of subjects: 599
Study 29295028 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior physical IPV experiences
Number of subjects: 599
Study 28530089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency repetitive transcranial magnetic stimulation (1 Hz rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 27
Study 28530089 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched non-disabled adults)
Number of subjects: 27
Study 28530089 — intervention group
Group type: COMPARATOR
Intervention: Parkinson's disease group (PD)
Number of subjects: 27
Study 27222510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide once daily
Number of subjects: 298
Study 27222510 — intervention group
Group type: COMPARATOR
Intervention: Insulin glulisine once daily
Number of subjects: 298
Study 27222510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide thrice daily
Number of subjects: 298
Study 27222510 — intervention group
Group type: COMPARATOR
Intervention: Insulin glulisine thrice daily
Number of subjects: 298
Study 27222510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 298
Study 27222510 — intervention group
Group type: COMPARATOR
Intervention: Insulin glulisine
Number of subjects: 298
Study 25116277 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings (23-32 mmHg)
Number of subjects: 80
Study 25116277 — intervention group
Group type: COMPARATOR
Intervention: No compression (NCG)
Number of subjects: 80
Study 25116277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CG and NCG)
Number of subjects: 80
Study 22884766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 100-600 mg coadministered with ketoconazole 400 mg
Number of subjects: 48
Study 22884766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 600 mg
Number of subjects: 48
Study 22884766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 100-600 mg
Number of subjects: 48
Study 22884766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib coadministered with ketoconazole
Number of subjects: 48
Study 22884766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20413736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (AT‐10)
Number of subjects: 60
Study 20413736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day (AT‐80)
Number of subjects: 60
Study 20413736 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine 8 g/day plus sitosterol 2.5 g/day
Number of subjects: 60
Study 20413736 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (AT‐10, AT‐80, cholestyramine plus sitosterol)
Number of subjects: 60
Study 17950677 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0865 25 mg
Number of subjects: 1521
Study 17950677 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0865 50 mg
Number of subjects: 1521
Study 17950677 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0865 75 mg
Number of subjects: 1521
Study 17950677 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 1521
Study 17950677 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0865 and esomeprazole
Number of subjects: 1521
Study 16215918 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 150
Study 16215918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 12377323 — intervention group
Group type: COMPARATOR
Intervention: 10 Gy single‐fraction radiotherapy (RT)
Number of subjects: 230
Study 12377323 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy in five fractions radiotherapy (RT)
Number of subjects: 230
Study 10343145 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy regimen of pantoprazole 40 mg (twice daily), clarithromycin 500 mg, and amoxicillin 1,000 mg for 1 week
Number of subjects: 57
Study 10343145 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy regimen of pantoprazole, clarithromycin, and amoxicillin
Number of subjects: 57
Study 8700082 — intervention group
Group type: EXPERIMENTAL
Intervention: Soothing, lyrical music played in the baby's bed during the experimental period
Number of subjects: 20
Study 1743759 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet
Number of subjects: 20
Study 1743759 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 6351517 — intervention group
Group type: EXPERIMENTAL
Intervention: Varidase solution
Number of subjects: 18
Study 6351517 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 18
Study 31987919 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 700
Study 31987919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder (BD) diagnosis
Number of subjects: 700